Work

Real-World Outcomes in Relapsed/Refractory DLBCL Patients Who Received Polatuzumab Vedotin PLUS Bendamustine and Rituximab or Tafasitamab Plus Lenalidomide By Line of Therapy

Year: 2022

Type: article

Study design: Observational Study

Source: Blood

DOI: 10.1182/blood-2022-167753

Authors: Mehdi Hamadani, Laura Liao, Lauren Wilson, Amanda Howarth, Carlos Flores, Lei Chen

Institution: Medical College of Wisconsin

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4310161887

FWCI: 1.36

Cites:

Cited by: 8

Related to: 10